CIPHER PHARMA WKN: A0B85L ISIN: CA17253X1050 Kürzel: PHE Forum: Aktien Thema: Hauptdiskussion

2 Zulassung für Medikamente innerhalb 4 Wochen erwartet = $$$$$ Cipher Pharma (CPH.TO) Markt-Kap: $37 M/ Cash $10 M / Shares Out 26 M / Profitabel Pharma / Marktzulassung für 2 weitere Produkte innerhalb von 4 Wochen erwartet = 300%+ Potenzial Cipher Pharma anticipates several key milestones in 2019 that will continue the growth of its Canadian commercial platform, including: Regulatory approval for plecanatide from Health Canada in Q4 2019 Regulatory approval for A-101 from Health Canada in Q4 2019 Commercial launch of XYDALBA (dalbavancin) North American top *** results for MOB-015 in Q4 2019 https://filecache.investorroom.com/mr5ircnw_cipher/217/IR%20Deck%20May%202019%20Final.pdf